Atrasentan: targeting the endothelin axis in prostate cancer.
Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cellular events such as proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and the alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biological and clinical activity in patients with prostate cancer has been demonstrated in a Phase III clinical setting by the suppression of markers of biochemical and clinical prostate cancer progression, and by a delay in time to disease progression, especially in patients with bone disease.
Jimeno
Antonio
A
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Bunting-Blaustein Cancer Research Building, Room 1M89, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.
Carducci
Michael
M
D000077868:Atrasentan; D002277:Carcinoma / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D019332:Endothelin-1 / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011759:Pyrrolidines / Q000627:therapeutic use*; D044022:Receptor, Endothelin A / Q000187:drug effects / Q000378:metabolism
D019332:Endothelin-1; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D000077868:Atrasentan